Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

An Altered AIDS Debate

November 2, 2001

"Rich countries have been so indifferent to the developing world's AIDS crisis that it is easy to overlook an instance in which they have done the right thing. In a speech on Tuesday Robert Zoellick, the administration's trade representative, announced two concessions to developing countries that cannot afford patented AIDS drugs. Provided they are implemented in good faith, these ought to be enough to silence the controversy on drug pricing that has consumed the AIDS debate. . . .

"Mr. Zoellick's first concession was that the world's poorest countries should have until 2016 to implement patent laws; previously, the World Trade Organization's rules had made 2006 the deadline. This means that for the next 14 years poor countries can buy cheap generic drugs without infringing patent law, since such laws will not exist. Second, Mr. Zoellick proposed a moratorium of at least five years on WTO challenges to African countries' efforts to fight AIDS and other killer diseases. This means that South Africa, a country that already has patent law, will be able to use the flexibility in its own statutes to access cheap drugs without being hauled before the WTO's dispute settlement panel.

"These two concessions do not help countries outside Africa that are too rich to qualify for the 10-year extension but still face a terrible AIDS toll. . . . But the US position does offer something to these countries: The draft declaration for the Doha summit reaffirms countries' right to circumvent patent rules in case of health emergencies such as AIDS. . . .

Advertisement
"The AIDS activists who have fought the US government over its support for international patents should now rethink their stance. They have moved policy away from a morally untenable insistence that poor countries espouse rich countries' patent system, and that is a triumph. . . . The danger now is that continued outrage against even a moderated international patent system will drive drug companies to withdraw from research into AIDS and other politically charged diseases. That would be a tragedy."


Back to other CDC news for November 2, 2001

Previous Updates

Adapted from:
Washington Post
11.02.01

  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

 

Advertisement